Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group

被引：0
|
作者：
Monique J. Roobol
F. H. Schröder
Jonas Hugosson
J. Stephen Jones
Michael W. Kattan
Eric A. Klein
Freddie Hamdy
David Neal
Jenny Donovan
Dipen J. Parekh
Donna Ankerst
George Bartsch
Helmut Klocker
Wolfgang Horninger
Amine Benchikh
Gilles Salama
Arnauld Villers
Stephen J. Freedland
Daniel M. Moreira
Andrew J. Vickers
Hans Lilja
Ewout W. Steyerberg
机构：
[1] Erasmus University Medical Centre,Department of Urology
[2] Sahlgrenska University Hospital,undefined
[3] Cleveland Clinic Foundation,undefined
[4] Oxford University,undefined
[5] Cambridge University,undefined
[6] Bristol University,undefined
[7] University of Texas Health Science Center at San Antonio,undefined
[8] Technische Universitaet Muenchen,undefined
[9] Innsbruck Medical University,undefined
[10] Hôpital Bichat-Claude Bernard,undefined
[11] Centre Hospitalier Intercommunal Castres-Mazamet,undefined
[12] Hôpital Huriez,undefined
[13] CHRU Lille,undefined
[14] Duke University,undefined
[15] Durham VA Medical Center,undefined
[16] Memorial Sloan-Kettering Cancer Center,undefined
来源：
World Journal of Urology | 2012年 / 30卷
关键词：
PSA; Risk; Prostate cancer; Prostate volume; Calibration; Net benefit;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：149 / 155
页数：6
相关论文
共 50 条
  • [31] On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer
    Bangma, Chris H.
    van Schaik, Ron H.
    Blijenberg, Bert G.
    Roobol, Monique J.
    Lilja, Hans
    Stenman, Ulf-Hakan
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (17) : 3109 - 3119
  • [32] COMPARISON OF RISK CALCULATORS FROM THE PROSTATE CANCER PREVENTION TRIAL AND THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER IN A CONTEMPORARY CANADIAN COHORT
    Trottier, Greg
    Roobol, Monique J.
    Lawrentschuk, Nathan
    Bostrom, Peter J.
    Fernandes, Kimberly A.
    Finelli, Antonio
    Chadwick, Karen
    Evans, Andrew
    van der Kwast, Theodorus H.
    Toi, Ants
    Zlotta, Alexandre R.
    Fleshner, Neil E.
    JOURNAL OF UROLOGY, 2011, 185 (04): : E769 - E769
  • [33] Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer
    Pasanen, Niko
    Talala, Kirsi
    Remmers, Sebastiaan
    Tammela, Teuvo L. J.
    Hugosson, Jonas
    Roobol, Monique J.
    Taari, Kimmo
    Godtman, Rebecka Arnsrud
    Bangma, Chris
    Auvinen, Anssi
    BJU INTERNATIONAL, 2024, 134 (02) : 291 - 299
  • [34] Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort
    Trottier, Greg
    Roobol, Monique J.
    Lawrentschuk, Nathan
    Bostroem, Peter J.
    Fernandes, Kimberly A.
    Finelli, Antonio
    Chadwick, Karen
    Evans, Andrew
    van der Kwast, Theodorus H.
    Toi, Ants
    Zlotta, Alexandre R.
    Fleshner, Neil E.
    BJU INTERNATIONAL, 2011, 108 (8B) : E237 - E244
  • [35] Prostate cancer mortality reduction by screening:: Power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial
    de Koning, HJ
    Liem, MK
    Baan, CA
    Boer, R
    Schröder, FH
    Alexander, FE
    INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (02) : 268 - 273
  • [36] The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group
    Vickers, Andrew J.
    Cronin, Angel M.
    Roobol, Monique J.
    Hugosson, Jonas
    Jones, J. Stephen
    Kattan, Michael W.
    Klein, Eric
    Hamdy, Freddie
    Neal, David
    Donovan, Jenny
    Parekh, Dipen J.
    Ankerst, Donna
    Bartsch, George
    Klocker, Helmut
    Horninger, Wolfgang
    Benchikh, Amine
    Salama, Gilles
    Villers, Arnauld
    Freedland, Steve J.
    Moreira, Daniel M.
    Schroder, Fritz H.
    Lilja, Hans
    CLINICAL CANCER RESEARCH, 2010, 16 (17) : 4374 - 4381
  • [37] ASSESSING THE VALIDITY OF THE PCPT AND ERSPC RISK CALCULATORS FOR PROSTATE CANCER IN A COHORT OF THE POPULATION AT HIGHEST RISK OF PROSTATE CANCER IN EUROPE
    Lundon, Dara
    Kelly, Brian
    Durkan, Garret
    Rogers, Eamon
    Walsh, Kilian
    JOURNAL OF UROLOGY, 2012, 187 (04): : E777 - E778
  • [38] Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Editorial Comment
    Penson, David F.
    JOURNAL OF UROLOGY, 2010, 184 (02): : 562 - 563
  • [39] Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish arm of the European randomised study of screening for prostate cancer (ERSPC)
    Pashayan, Nora
    Pharoah, Paul D. P.
    Schleutker, Johanna
    Talala, Kirsi
    Tammela, Teuvo L. J.
    Maattanen, Liisa
    Harrington, Patricia
    Tyrer, Jonathan
    Eeles, Rosalind
    Duffy, Stephen W.
    Auvinen, Anssi
    CANCER RESEARCH, 2015, 75
  • [40] A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European randomized study of prostate cancer screening (ERSPC) in Goteborg, Sweden
    Vickers, Andrew J.
    Cronin, Angel M.
    Aus, Gunnar
    Pihl, Carl G.
    Becker, Charlotte
    Pettersson, Kim
    Scardino, Peter T.
    Hugosson, Jonas
    Lilja, Hans
    JOURNAL OF UROLOGY, 2008, 179 (04): : 719 - 719
12345